Edwards Lifesciences Q2 FY2026 Earnings Call Summary
EW
NYSE
Healthcare
📅 2026-07-23
⏱ ~60 sec read
🟢 Bullish
⏱️ 60-Second Brief
Edwards Lifesciences · Q2 FY2026
Stock Next Day
▼ 0.77%
$83.82 → $83.18
Revenue
$1.74B
✅ Beat
EPS
$691.2
AI Sentiment
🟢 Bullish
Despite some headwinds, the company's strong sales growth, s…
📌 Bottom Line:
Edwards Lifesciences reported stronger-than-expected second-quarter sales growth of 13.6% to $1.74 billion, driven by robust performance across its TAVR, TMTT, and Surgical segments. The company also raised its full-year…
🤖 AI-Assisted Summary — Produced using a custom AI pipeline by Abhi, reviewed for accuracy.
·
⚠️ Not financial advice. For informational purposes only.
Full Disclaimer →
📋 TL;DR — What Happened
Edwards Lifesciences reported stronger-than-expected second-quarter sales growth of 13.6% to $1.74 billion, driven by robust performance across its TAVR, TMTT, and Surgical segments. The company also raised its full-year sales and TAVR/TMTT guidance, signaling confidence in its comprehensive portfolio and strategic execution.
📊 Key Financial Metrics
Revenue
$1.74B
✅ Beat
EPS (Diluted)
$691.2
YoY Revenue Growth
13.6%
Gross Margin
77.6%
Net Income
$241.9M
AI Sentiment
🟢 Bullish
Despite some headwinds, the company's strong sales growth, significant TMTT expansion, positive clinical data, and increased full-year guidance demonstrate robust operational performance and future potential.
✅ What Went Well
Robust Sales Growth Across Segments: Edwards Lifesciences achieved impressive total company sales growth of 13.6% to $1.74 billion, with constant currency sales up 12.5%. This growth was broad-based, supported by strong performance in TAVR (11.3% growth to $1.26 billion), TMTT (47.3% growth to $195.9 million), and Surgical (6.5% growth to $284 million), demonstrating the strength of its diversified portfolio.
Exceptional TMTT Performance and Pipeline: The Transcatheter Mitral and Tricuspid Therapies segment was a standout, with sales surging 47.3% compared to the prior year. This was driven by strong physician enthusiasm and increasing adoption of the PASCAL system, as well as the successful scaling of the EVOQUE system. The company also anticipates Q4 approvals for PASCAL tricuspid indication and next-generation PASCAL with Capture Clarity, signaling continued innovation.
Positive Clinical Data and Market Leadership: Recent clinical presentations, such as the PARTNER 3 trial sub-analysis at New York Valves, reinforced the best-in-class performance and long-term durability of Edwards' SAPIEN TAVR platform. Additionally, 10-year data from the COMMENCE trial highlighted the extended durability of RESILIA tissue, further solidifying the company's leadership in structural heart innovation and supporting proactive disease management.
⚠️ Concerns & Risks
Increased Effective Tax Rate and Regulatory Impact: The company now expects its 2026 effective tax rate to be at the high end of its previous 16% to 19% range. This increase is attributed to an expectation that side-by-side safe-harbor taxation legislation related to Pillar Two will not come into effect before year-end, and changes to California law restricting the usage of R&D credits, which could impact future profitability.
Foreign Exchange Headwinds on Gross Margin: While the reported gross profit margin was 77.5% (77.6% adjusted), consistent with the prior year, the company anticipates its full-year gross profit margin to be at the lower end of its 78% to 79% guidance. This is primarily driven by the impacts of foreign exchange through its hedging program, indicating external currency fluctuations are a persistent challenge.
Ongoing Litigation and Impairment Charges: Edwards Lifesciences reported $6.3 million in certain litigation expenses for the quarter, related to intellectual property and other legal matters. Additionally, a $40.0 million loss on impairment was recorded due to the company's decision not to exercise an option to acquire one of its variable interest entities (VIE), which negatively impacted GAAP net income and diluted EPS.
🔮 CEO / Management Guidance
Edwards Lifesciences increased its full-year 2026 constant currency sales growth guidance to 10% to 11% from 9% to 11%, and raised TAVR and TMTT sales guidance. The company reaffirmed its adjusted EPS guidance of $2.95 to $3.05, despite anticipating a higher effective tax rate.
💬 Key Quote
We delivered stronger-than-expected second quarter sales growth of 12.5%. As Edwards continues to invest in new structural heart therapies and expand adoption globally, our results increasingly reflect the strength of our comprehensive portfolio and agile execution, with growth supported by therapies across TAVR, mitral, tricuspid and surgical, as well as meaningful contributions from each of the regions. — Bernard Zovighian, CEO
🏢 About Edwards Lifesciences
Edwards Lifesciences (EW) is a publicly listed company on the NYSE exchange in the Healthcare sector. EarningsBloom tracks its quarterly earnings calls to provide free AI-generated summaries for investors.
📈 Want to act on this insight?
Topics:
Transcatheter Aortic Valve Replacement (TAVR)
Transcatheter Mitral and Tricuspid Therapies (TMTT)
Medical Device Innovation
Clinical Trials & Product Durability
📁 More from Edwards Lifesciences
View all earnings summaries for Edwards Lifesciences →